162 related articles for article (PubMed ID: 9389377)
21. Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.
Pitts RC; Allen RM; Walker EA; Dykstra LA
J Pharmacol Exp Ther; 1998 Jun; 285(3):1197-206. PubMed ID: 9618423
[TBL] [Abstract][Full Text] [Related]
22. Reversibility of opioid receptor occupancy of buprenorphine in vivo.
Englberger W; Kögel B; Friderichs E; Strassburger W; Germann T
Eur J Pharmacol; 2006 Mar; 534(1-3):95-102. PubMed ID: 16490191
[TBL] [Abstract][Full Text] [Related]
23. Antinociceptive tolerance to the mu-opioid agonist DAMGO is dose-dependently reduced by MK-801 in rats.
Mao J; Price DD; Lu J; Mayer DJ
Neurosci Lett; 1998 Jul; 250(3):193-6. PubMed ID: 9708865
[TBL] [Abstract][Full Text] [Related]
24. Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.
Ko MC; Butelman ER; Traynor JR; Woods JH
J Pharmacol Exp Ther; 1998 May; 285(2):518-26. PubMed ID: 9580592
[TBL] [Abstract][Full Text] [Related]
25. In vivo apparent pA2 analysis in rats treated with either clocinnamox or morphine.
Walker EA; Richardson TM; Young AM
Psychopharmacology (Berl); 1996 May; 125(2):113-9. PubMed ID: 8783384
[TBL] [Abstract][Full Text] [Related]
26. Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of
Gerak LR; Minervini V; Latham E; Ghodrati S; Lillis KV; Wooden J; Disney A; Husbands SM; France CP
J Pharmacol Exp Ther; 2019 Nov; 371(2):507-516. PubMed ID: 31439807
[TBL] [Abstract][Full Text] [Related]
27. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
28. Developmental change of mu opioid receptors in neonatal guinea pig brain stem.
Murphey LJ; Olsen GD
Brain Res Dev Brain Res; 1995 Mar; 85(1):146-8. PubMed ID: 7781163
[TBL] [Abstract][Full Text] [Related]
29. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
Chen SR; Pan HL
J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
[TBL] [Abstract][Full Text] [Related]
30. 3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy.
Husbands SM; Sadd J; Broadbear JH; Woods JH; Martin J; Traynor JR; Aceto MD; Bowman ER; Harris LS; Lewis JW
J Med Chem; 1998 Aug; 41(18):3493-8. PubMed ID: 9719602
[TBL] [Abstract][Full Text] [Related]
31. Methoclocinnamox: agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys.
Butelman ER; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Nov; 279(2):934-8. PubMed ID: 8930202
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling.
Yabaluri N; Medzihradsky F
Mol Pharmacol; 1997 Nov; 52(5):896-902. PubMed ID: 9351981
[TBL] [Abstract][Full Text] [Related]
33. Signal transduction efficacy of the highly potent mu opioid agonist 14-methoxymetopon.
Zernig G; Saria A; Krassnig R; Schmidhammer H
Life Sci; 2000 Mar; 66(19):1871-7. PubMed ID: 10809184
[TBL] [Abstract][Full Text] [Related]
34. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
35. Effect of morphine tolerance and abstinence on the binding of [3H]naltrexone to discrete brain regions and spinal cord of the rat.
Reddy PL; Veeranna ; Matwyshyn GA; Thorat SN; Bhargava HN
Gen Pharmacol; 1994 Mar; 25(2):355-61. PubMed ID: 8026736
[TBL] [Abstract][Full Text] [Related]
36. Spinal opioid mu receptor expression in lumbar spinal cord of rats following nerve injury.
Porreca F; Tang QB; Bian D; Riedl M; Elde R; Lai J
Brain Res; 1998 Jun; 795(1-2):197-203. PubMed ID: 9622629
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
Mjanger E; Yaksh TL
J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
[TBL] [Abstract][Full Text] [Related]
38. The role of central mu opioid receptors in opioid-induced itch in primates.
Ko MC; Song MS; Edwards T; Lee H; Naughton NN
J Pharmacol Exp Ther; 2004 Jul; 310(1):169-76. PubMed ID: 15044556
[TBL] [Abstract][Full Text] [Related]
39. Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice.
Narita M; Mizoguchi H; Narita M; Sora I; Uhl GR; Tseng LF
Br J Pharmacol; 1999 Jan; 126(2):451-6. PubMed ID: 10077238
[TBL] [Abstract][Full Text] [Related]
40. The effects of aging on mu and delta opioid receptors in the spinal cord of Fischer-344 rats.
Hoskins DL; Gordon TL; Crisp T
Brain Res; 1998 Apr; 791(1-2):299-302. PubMed ID: 9593954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
